Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States. [PDF]
Weiss GJ.
europepmc +1 more source
Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer. [PDF]
Smoragiewicz M +17 more
europepmc +1 more source
Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors. [PDF]
Siskin M +5 more
europepmc +1 more source
Association of <i>HSD3B1</i> rs1047303 polymorphism with prognosis in metastatic prostate cancer: A systematic review and meta-analysis. [PDF]
Feng F, Wang Y, Yang F, Nie Y.
europepmc +1 more source
Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System). [PDF]
Ahmed Z +6 more
europepmc +1 more source
Pharmacokinetic and bioequivalence evaluation of two abiraterone acetate tablets under fasting conditions in healthy Chinese volunteers. [PDF]
Shi J +7 more
europepmc +1 more source
Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates. [PDF]
Sharaf B +8 more
europepmc +1 more source
Abiraterone or Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer: A Nationwide Veterans Affairs Study. [PDF]
La J +7 more
europepmc +1 more source
Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer. [PDF]
Gao Y +16 more
europepmc +1 more source
Zero-premium Medicare Advantage plans and access to generic abiraterone and imatinib. [PDF]
Jiang C +6 more
europepmc +1 more source

